Oct 1, 2025 · 44 min
Jabil bets on AI infrastructure as Cramer weighs market winners
Mad Money w/ Jim Cramer 10/1/25
The episode connects AI hardware demand, domestic manufacturing, corporate turnarounds, and defensive health care investing across a volatile market.
- 1Jabil’s AI infrastructure work and planned U.S. investment illustrate how contract manufacturing is moving up the technology value chain.
- 2Nike’s operating progress becomes a test of whether credible execution can outweigh consumer pressure, tariffs, and leadership concerns.
- 3Drug makers offer a potential defensive angle, but pricing politics and research costs complicate the sector’s safe-haven case.
Don't miss
Mike Dastoor explains how Jabil is supporting AI hardware and data centers while planning a $500 million U.S. manufacturing investment.
The brief
Jim Cramer opens by using quarterly winners and losers as a guide to market interpretation, then answers viewer questions about Micron and financial-services stocks.
Jabil CEO Mike Dastoor discusses the contract manufacturer’s role in AI hardware, data centers, health care, and GLP-1 devices, alongside a planned $500 million U.S. investment.
Nike’s strong earnings prompt a broader turnaround test: can better leadership and operating execution overcome consumer concerns, tariffs, and pressure across apparel stocks?
A rapid-fire round covers Tencent Music, Sunrun, Inspire Medical Systems, Microvast, Veradigm, Thermo Fisher, Danaher, and Atlassian through brief buy, hold, or avoid judgments.
The episode closes on drug makers as possible defensive investments, weighing health care’s resilience against drug-pricing politics, research costs, and economic uncertainty.
What was said on this episode
47 statements · 32 positive · 13 negative · 2 mixed
Third-quarter winners are often bought by money managers in the fourth quarter.
“the winners of the third quarter are often bought in the fourth quarter by money managers who want to show their clients that they own the right stocks”
Listen at 1:01
Drug stocks may continue rising.
“The drug stocks may have more room to run.”
Listen at 1:35
AppLovin’s stock is likely to keep outperforming short sellers.
“I would not bet against this app, Love & Stock, even if it's been the target of short sellers who have been run over by the buyers. And I think it's going to stay that way.”
Listen at 2:15
Combining Warner Bros. Discovery and Paramount would create an unrivaled studio business.
“I think you combine the two entertainment companies, create an unrivaled studio business”
Listen at 3:46
Corning will eventually replace copper inside data-center semiconductor clusters.
“I think it's almost a foregone conclusion that one day Corning will replace the copper inside the immense clusters of semiconductors, NVIDIA product, in the data center.”
Listen at 4:29
Robinhood has led brokerages in appealing to customers seeking broad asset access.
“Robinhood's been the most forward in its appeal to those who want to own pretty much anything, especially crypto.”
Listen at 5:26
Chipotle is positioned for a potential stock-price reversal.
“Chipotle seems like a decent reversal candidate.”
Listen at 7:22
Most third-quarter winners will continue rallying through year-end.
“I'm betting most of these can keep rallying through the end of the year.”
Listen at 7:44
Micron is a strong buy-and-hold investment with a $200 target.
“I think this guy sucks. Got $200 written all over it. This is just a great buy and hold slash homework.”
Listen at 8:29
The discussed financial-services stock is a good stock to own.
“is it a good stock to own? And the answer is absolutely yes.”
Listen at 9:37
Jabil’s post-earnings decline was largely caused by profit-taking.
“I think a lot of it is just profit-taking”
Listen at 11:32
Jabil is central to the AI hardware ecosystem.
“we're actually at the heart of AI hardware ecosystem”
Listen at 13:02
Jabil is the world’s largest GLP-1 injector manufacturer, producing 500 million annually.
“with the largest GLP-1 injector manufacturer in the world, we make 500 million units per year.”
Listen at 14:20
Jabil employs more than 10,000 engineers worldwide.
“today in the whole company, we have. almost 10,000-plus engineers in total.”
Listen at 15:25
Jabil provides end-to-end engineering and industrialization from early product concepts.
“Today, they come to us with a concept. They come to us with a design. So the product isn't even ready. And we help them engineer it.”
Listen at 15:56
Jabil plans to invest $500 million in U.S. cloud and AI manufacturing.
“you announced a planned multi-year $500 million investment in U.S. manufacturing for cloud and AI data center infrastructure”
Listen at 16:28
Jabil’s planned facility has generated exceptionally high CEO interest.
“the demand expectations. I'm already getting calls from CEOs. Everyone's trying to, hey, what can we. What can we do there? And the level of interest just an announcement has created is actually off the charts.”
Listen at 18:02
Nike’s early results validate Elliott Hill’s turnaround changes.
“I think it's great proof of concept the changes Elliott is making.”
Listen at 20:27
Nike’s running-shoe business is making a major comeback.
“the running shoe business is already making a major comeback.”
Listen at 22:15
Nike’s turnaround remains at an early stage and will take time.
“Turnarounds take a long time. This is really just the beginning.”
Listen at 22:59
Cramer is adding to Nike because earnings increased his turnaround confidence.
“After last night's earnings report, I feel a lot more confident in Nike's ability to turn itself around, which is why we're adding to our position in this one.”
Listen at 25:32
Nike’s stock can rise from $74 to $100.
“I'm betting a $74 stock can go to $100.”
Listen at 26:01
Peloton’s stock is unlikely to rise from current levels.
“So I'm going to say no.”
Listen at 26:40
Fermi is more a business plan than an operating business.
“I think it's kind of more of a business plan than an actual business.”
Listen at 29:17
Fermi is likely to remain without a substantial operating business for some time.
“it's likely to remain that way for quite some time.”
Listen at 29:22
Fermi’s nuclear projects will not operate before the 2030s.
“it will take at least until the 2030s before anything's up and running.”
Listen at 29:49
Fermi’s nuclear projects will likely take longer than projected.
“I think that's actually optimistic, given that these projects almost always take much longer than expected.”
Listen at 29:53
Fermi lacks a sufficiently developed operating business.
“this is more of a business plan than a business.”
Listen at 30:43
Investors should avoid Fermi.
“I want to steer clear of this one.”
Listen at 33:46
Fermi’s business plan does not justify a $19 billion valuation.
“no business plan is worth $19 billion.”
Listen at 34:03
Fermi is too immature for Cramer to recommend.
“this one's way too early, frankly, and too, let's say, half-baked for me to feel comfortable recommending it.”
Listen at 34:43
Investors should prefer Alibaba over Tencent Music for China exposure.
“We're moving on. We're going to stick with Baba when it comes to China.”
Listen at 36:01
Sunrun is reasonably attractive and not expensive.
“it's not a bad stock, and it's not expensive.”
Listen at 36:29
Cramer is uncertain whether GLP-1 drugs are hurting Inspire Medical Systems.
“Let me do some work on it to see whether Inspire's really being hurt by the GOP-1s or not.”
Listen at 36:53
Investors should hold Microvast.
“I'd hold on to it.”
Listen at 37:27
Veradigm’s stock is likely to rise substantially.
“Verda, I think, is going much higher.”
Listen at 37:34
Danaher currently has better prospects than Thermo Fisher.
“Danaher, I think, has got more going for it right now than Thermo Fisher.”
Listen at 38:28
Investors should choose Danaher.
“I would do DHR. It's a club name.”
Listen at 38:32
AI competition is undermining Atlassian’s stock appeal.
“People feel that they can create their own product that's just as good as team using artificial intelligence. That's why I no longer recommend the stock of team.”
Listen at 39:27
Investors should consider Eli Lilly because of its GLP-1 drug.
“I suggest, for example, that you consider Eli Lilly because of its remarkable GOP-1 diabetes and weight loss drug.”
Listen at 41:32
Eli Lilly’s GLP-1 drug could eventually treat hypertension, dementia, and alcoholism.
“I think it could be used for everything from the silent killer of hypertension to dementia and, yes, alcoholism.”
Listen at 41:42
A successful oral GLP-1 pill could lift Lilly’s market cap above $1 trillion.
“a successful pill could take Lilly's market cap. from $781 billion, where it is now, into the trillion-dollar winner's circle.”
Listen at 42:10
Eli Lilly remains worth buying at its current valuation.
“That makes it worth buying even up here.”
Listen at 42:18
Johnson & Johnson’s asbestos and baby-powder litigation risk has peaked.
“I believe the risk from this asbestos and the baby powder litigation has crested.”
Listen at 42:36
Merck and Danaher have substantial further upside.
“I believe they've got a lot more upside before they run out of steam.”
Listen at 43:02
Danaher could fall back to the 180s without benefiting from new drug companies.
“It needs to demonstrate it can capitalize off of all the new drug companies coming public right now, or it will go back to the 180s.”
Listen at 43:10
Investors should wait for a pullback before buying drug stocks.
“I think you should maybe wait for the next pullback and pounce.”
Listen at 43:31
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Books & mentions
Some links are affiliate links — PodLume may earn a commission if you buy.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.